There were 61 press releases posted in the last 24 hours and 183,278 in the last 365 days.

Global Hemophilia Therapeutics Market 2017-2022 By Drug, Type of Hemophilia, Treatment, & Therapy Outlook

/EIN News/ -- Dublin, May 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Hemophilia Therapeutics Market By Drug, By Type of Hemophilia, By Treatment, By Therapy Outlook 2022" report to their offering.

Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged bleeding due to the lack of factors required for the clotting of blood. According to World Federation of Hemophilia, about one in 10,000 people are born with this disease. Various types of drugs are injected into the veins of patient in order to replace the clotting factors, which are missing or low in number.

As per this report Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction Therapy) Outlook 2022, the global hemophilia therapeutics market is anticipated to witness a moderate growth during 2016-2022.

This report provides a detailed analysis of the current and future market scenario of the global hemophilia therapeutics market. The report provides insight about the major drivers, such as increasing awareness about hemophilia and its treatment options, grants and tax credits, for the global hemophilia therapeutics market. Furthermore, few challenges, such as manufacturing difficulties and low switching rate between hemophilia medicines, which are hindering the growth of the global hemophilia therapeutics market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global hemophilia therapeutics market.

The global hemophilia therapeutics market has been segmented on the basis of type of hemophilia, i.e. Hemophilia A, Hemophilia B, and Others. Hemophilia A occupies the largest share in the global hemophilia therapeutics market, owing to the highest prevalence of this type of hemophilia. Moreover, strong pipeline of drugs for Hemophilia A is also helping its market to grow all across the globe.

Furthermore, the global hemophilia therapeutics market has also been segmented on the basis of type of treatment. According to the report, the treatment for hemophilia can either be an on-demand treatment or a prophylaxis treatment. Currently, on-demand treatment dominates the global hemophilia therapeutics market, as patients usually go for treatment only when bleeding episodes occur. However, prophylaxis is forecasted to be the fastest growing segment owing to the requirement of better management of bleeding episodes.

Similarly, the market has also been segmented on the basis of type of therapy into replacement therapy and immune tolerance induction therapy. Apart from these types of therapies, efforts are also being made by various pharmaceutical and biotech companies to develop gene therapy for the treatment of hemophilia. Gene therapy is an evolving field which focuses on correcting defective genes in order to cure genetic diseases, such as hemophilia. Use of gene therapy for hemophilia treatment is a promising option, as hemophilia is caused due to a single genetic defect. Even a minimal success from this procedure can mean significant improvement in quality of life for patients. Numerous companies, such as BioMarin Pharmaceuticals and uniQure, are carrying out clinical trials for gene therapies for the treatment of hemophilia. Hence, gene therapy presents great opportunities for the growth of global hemophilia therapeutics market in the coming years.

The last section of the report discusses about the prominent players in global hemophilia therapeutics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hemophilia therapeutics market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Hemophilia: An Overview

4. Market Dynamics
4.1 Drivers
4.1.1 Development of Inhibitors in Hemophilia Patients
4.1.2 Rising Healthcare Expenditure
4.1.3 Increasing Awareness
4.1.4 Rising Life Expectancy
4.1.5 Grants and Tax Credits
4.1.6 Shorter Development Timeline and Orphan Drug Exclusivity (ODE)
4.2 Challenges
4.2.1 Manufacturing Difficulties
4.2.2 Low Switching Rate
4.3 Opportunities
4.3.1 Incessant Launch of New Generation of Recombinant Factor Products
4.3.2 Growing Geriatric Population

5. Global Hemophilia Therapeutics Market Outlook 2022

6. Major Products in Hemophilia Therapeutics Market
6.1 Advate
6.2 NovoSeven/NovoSeven RT
6.3 Kogenate/Kovaltry
6.4 Feiba
6.5 BeneFix
6.6 ReFacto AF/Xyntha
6.7 Eloctate/Elocta
6.8 Alprolix
6.9 Alphanate
6.10 Rixubis
6.11 NovoEight
6.12 Adynovate/Adynovi

7. Market Segmentation by Type of Hemophilia
7.1 Hemophilia A
7.2 Hemophilia B
7.3 Others

8. Market Segmentation by Type of Treatment
8.1 On-Demand
8.2 Prophylaxis
9. Market Segmentation by Type of Therapy
9.1 Replacement Therapy
9.2 Immune Tolerance Induction Therapy

10. Market Segmentation by Geography
10.1 North America
10.2 Europe
10.3 Asia-Pacific

11. Gene Therapy - Future of Hemophilia Treatment

12. Trends & Developments

13. Mergers & Acquisitions

14. Pipeline Analysis

15. Company Profiles
15.1 Novo Nordisk A/S
15.2 Pfizer Inc.
15.3 F. Hoffmann-La Roche Ltd.
15.4 Bayer AG
15.5 Shire plc
15.6 CSL Limited
15.7 Octapharma AG
15.8 Grifols International SA
15.9 Swedish Orphan Biovitrum AB
15.10 Alnylam Pharmaceuticals, Inc.

For more information about this report visit

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Hematological Drugs 

Primary Logo